A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Teicoplanin is a glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall peptidoglycan synthesis. It is used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Teicoplanin is widely available in many European, Asian, and South American countries, however it is not currently approved by the US Food and Drug Administration and is not commercially available in the United States. Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Other trade names include Ticocin marketed by Cipla(India). Its strength is considered to be due to the length of the hydrocarbon chain.
Such treatment reduces the risk of death. Additionally, they may benefit from cognitive behavioral therapy, other forms of support from mental health professionals such as individual or group therapy, twelve-step programs, and other peer support programs. The medication naltrexone may also be useful to prevent relapse. Naloxone is useful for treating an opioid overdose and giving those at risk naloxone to take home is beneficial. This disorder is much more prevalent than first realized. In 2020, the CDC estimated that nearly 3 million people in the U.S. were living with OUD and more than 65,000 people died by opioid overdose, of whom more than 15,000 overdosed on heroin. In 2022, the U.S. reported 81,806 deaths caused by opioid-related overdoses. Canada reported 32,632 opioid-related deaths between January 2016 and June 2022.
=== Herpes zoster === Herpes zoster (shingles) most often occurs in the elderly and is only rarely seen in children. The incidence of herpes zoster in vaccinated adults is 0.9/1000 person-years, and is 0.33/1000 person-years in vaccinated children; this is lower than the overall incidence of 3.2–4.2/1000 person-years. The risk of developing shingles is reduced for children who receive the varicella vaccine, but not eliminated. The CDC stated in 2014: "Chickenpox vaccines contain weakened live VZV, which may cause latent (dormant) infection. The vaccine-strain VZV can reactivate later in life and cause shingles. However, the risk of getting shingles from vaccine-strain VZV after chickenpox vaccination is much lower than getting shingles after natural infection with wild-type VZV." The risk of shingles is significantly lower among children who have received varicella vaccination, including those who are immunocompromised. The risk of shingles is approximately 80% lower among healthy vaccinated children compared to unvaccinated children who had wild-type varicella. A population with high varicella vaccination also has lower incidence of shingles in unvaccinated children, due to herd immunity.
Some methods of creating a trophy mount do not involve preserving the actual body of the animal. Instead, detailed photos and measurements are taken of the animal so a taxidermist can create an exact replica in resin or fiberglass that can be displayed in place of the real animal. No animals are killed in the creation of this type of trophy mount. One situation where this is practiced is in the world of sport fishing where catch and release is becoming increasingly prevalent. Reproduction mounts are commonly created for (among others) trout, bass, and large saltwater species such as the swordfish and blue marlin. Another situation where reproduction trophies are created is when endangered species are involved. Endangered and protected species, such as the rhinoceros, are hunted with rifles loaded with tranquilizer darts rather than real bullets. While the animal is unconscious, the hunter poses for photos with the animal while it is measured for the purpose of creating a replica, or to establish what size of prefabricated fiberglass trophy head can be purchased to most closely approximate the actual animal. The darted animal is not harmed. The hunter then displays the fiberglass head on the wall in lieu of the real animal's head to commemorate the experience of the hunt.
Sources: en.wikipedia.org
== Reception == The film received a mixed critical reaction. Rotten Tomatoes gives it a score of 48% based on 21 reviews, with an average rating of 4.89/10. Jeanette Catsoulis of The New York Times praised Chastain's performance, noting that she "digs deep. Surrendering to her character’s smoky voice-over and disastrous judgment, the actress finds pockets of soul in a role that’s part Jessica Rabbit, part Marilyn Monroe." Rex Reed of The New York Observer rated the film three out of four stars. Reed praised the casting; "This movie boasts a terrific cast, and Ms. Chastain not only holds her own corner of every scene, she's the only thing you want to watch."
=== Uniqueness of venom === Centipede venom generally contains a few different enzymes that are very different from other arthropods, where metalloprotease, an enzyme that breaks down protein plays an important role. Centipede venom has effects on skeletal muscles, heart muscles, and neurons, and the effects are attributed to the larger protein molecules in the venom. Venoms of S. mutilans contain a diverse range of neurotoxins, including 26 neurotoxin-like peptides that belong to 10 different groups. Most of the 26 identified neurotoxin-like peptides have a different molecular structure compared to the neurotoxins found in spiders, snakes, scorpions, marine cone snails, and sea anemones. The functional mechanism of these peptides are similar to the neurotoxins of the mention venomous animals, yet their primary structures remain unique. A few were found to contain insecticidal properties and act on voltage-gated sodium, potassium, and calcium channels. It was found that both purified neurotoxins and unprocessed centipede venom are highly insecticidal, with the unprocessed venom being significantly stronger than all purified neurotoxins in insecticidal effects. Centipede venoms might have the potential to provide peptide candidates with potential pharmaceutical or agrochemical uses due to their high level of biochemical diversity.
Often the analyte displays a reversible CV wave (such as that depicted in Figure 1), which is observed when all of the initial analyte can be recovered after a forward and reverse scan cycle. Although such reversible couples are simpler to analyze, they contain less information than more complex waveforms. The waveform of even reversible couples is complex owing to the combined effects of polarization and diffusion. The difference between the two peak potentials (Ep), ΔEp, is of particular interest.
It was this achievement that earned him his first Nobel prize in Chemistry in 1958. This discovery was crucial to the later sequence hypothesis of Francis Crick for developing ideas of how DNA codes for proteins.
In addition to studying chromosomes to the level of individual genes, genetic testing in a broader sense includes biochemical tests for the possible presence of genetic diseases, or mutant forms of genes associated with increased risk of developing genetic disorders. Genetic testing identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. As of 2011 several hundred genetic tests were in use. Since genetic testing may open up ethical or psychological problems, genetic testing is often accompanied by genetic counseling.
Sources: en.wikipedia.org
=== 1980s to 2000s: International Expansion === In 1987, Whirlpool began selling compact washers in India and acquired a majority interest in Inglis of Canada. In 1988, Whirlpool bought a 53% stake in the large-appliance division of Philips N.V., creating a joint venture called Whirlpool International. The purchase made Whirlpool the world's largest manufacturer of major appliances, with annual sales of approximately $6 billion. The remaining 47% stake was purchased from Philips in 1991, completing the acquisition. In 1989, Whirlpool acquired the Roper brand and Bauknecht of Germany. Whirlpool entered the Indian market in the late 1980s as part of its global expansion strategy. It founded a joint venture with the TVS Group and established the first Whirlpool manufacturing facility in Puducherry, where it manufactured washing machines. In 1995, Whirlpool acquired Kelvinator India Limited, marking an entry into the refrigerator market as well. That same year, the company acquired major shares in TVS joint venture, and in 1996, the Kelvinator and TVS acquisitions were merged to create Whirlpool of India Limited. This expanded the company's portfolio on the Indian subcontinent to include washing machines, refrigerators, microwave ovens, and air conditioners. Whirlpool of India Limited is headquartered in Gurgaon, and it owns three manufacturing facilities at Faridabad, Puducherry and Pune. The Pune opened most recently, in 2022. In 1997, the company acquired a majority stake in Embraco, a Brazilian maker of compressors for refrigeration.
Marrow stole parts from bicycles and assembled "three or four weird-looking, brightly-painted bikes" from the parts; his father either did not notice or never acknowledged this. When Marrow was 13 years old, Solomon also died of a heart attack. Following his father's death, the orphaned Marrow briefly lived with a nearby aunt, then was sent to live with his other aunt and her husband in View Park-Windsor Hills, an upper middle-class Black neighborhood in South Los Angeles. While his cousin Earl was preparing to leave for college, Marrow shared a bedroom with him. Earl was a fan of rock music and listened only to the local rock radio stations; sharing a room with him sparked Marrow's interest in heavy metal music.
=== Domestic reception === The Lahore Chamber of Commerce & Industry (LCCI) called the deal a game-changer, citing improved trade balance, job creation, and export growth opportunities. The Pakistan Stock Exchange (KSE-100) rallied—rising by 978 points—as investors welcomed the trade and energy partnership.
Matrine and matrine oxide, quinolizidine alkaloids found in the roots Kushenin, a pterocarpan and isoflavonoid Sophoraflavanone G 7,9,2',4'-Tetrahydroxy-8-isopentenyl-5-methoxychalcone Sophoridine Kurarinone Trifolirhizin, a pterocarpan flavonoid, isolated from the roots 8-Prenylkaempferol, a prenylflavonoid Oxysophocarpine and sophocarpine, alkaloids
diplonema Also diplotene stage. In meiosis, the fourth of the five substages of prophase I, following pachynema and preceding diakinesis. During diplonema, the synaptonemal complex disassembles and the paired homologous chromosomes begin to separate from one another, though they remain tightly bound at the chiasmata where crossover has occurred.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.